Vir Biotechnology

VIR

Biotechnology · Healthcare

Price

$9.78

+0.57 (+6.19%)

Market Cap

$1.65B

Exchange

NASDAQ

Winston Score

Winston is serious

Mixed quality — meaningful strengths and weaknesses.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Good

Growth

Good

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+3.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 133.4M (2021) → 138.5M (2025)

Winston Score History

The full picture

Vir Biotechnology is a clinical-stage biotech company focused on developing treatments for infectious diseases. Its main areas of research include hepatitis B, HIV, and respiratory viruses. The company gained attention during the COVID-19 pandemic for co-developing sotrovimab, an antibody treatment, with GlaxoSmithKline.

Vir makes money primarily through collaboration agreements and milestone payments from partners like GSK, rather than selling its own approved products at scale. It operates mainly in the United States, with research partnerships extending globally. The company is still spending heavily to advance its pipeline, which explains the deeply negative operating margin. Its main competitive edge is its antibody discovery platform, which is designed to identify treatments that work against multiple strains of a virus. The biggest risk Vir faces is that its pipeline candidates could fail in clinical trials, which would leave it without a clear path to generating its own product revenue.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

>+1,000% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+160.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$433M/ year

↓ Declining (-15% vs prior year)

631.3% of revenue

35.1x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

23.7%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

5+ years

Quarterly Free Cash Flow

↑ Burn rate improving

$1.0B cash & investments at current burn rate

Revenue accelerating

Vir Biotechnology grew revenue 19583% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Profit after running costs

Operating Margin

30.7%

Excellent — 30.7% operating margin

Return on the money invested

ROCE

-27.5%

Weak — -27.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

>+1,000%

Fast-growing sales (>+1,000% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-112.3%

Burning cash (-112.3%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial